British Peripheral Nerve Society

BPNS meeting joint with Belgian-Dutch Neuromuscular Group

Start Date

End Date

Friday 11 Mar 2016 09:30 AM

Friday 11 Mar 2016 18:00 PM

Location

Cambridge

Details

Dear Friends and Colleagues,

We look forward to welcoming you to the Spring 2016 Meeting of the British Peripheral Nerve Society, which will be held on Friday 11th March 2016 at Corpus Christi College, Cambridge, UK. The meeting will start at 10.00 (coffee from 09.30) and finish around 18.00.

Registration has now closed. We are grateful for sponsorship from the pharmaceutical industry to allow us to keep the registration fee low.

This meeting will be held jointly with the Belgian-Dutch Neuromuscular Group and will include an enjoyable mixture of clinical case presentations, lectures and discussion on clinical aspects of peripheral nerve disease. The full programme is now available for downloading below. Guest speakers will include Hessel Franssen on 'Node and neuropathy', David Bennett on 'Clinical aspects of small fibre neuropathy', and Ingemar Merkies on 'Monitoring outcome measures in clinical practice' with audience participation in an open discussion session on this topic.

The deadline for abstract submission has now passed. Please note that consent is required from any living patient to be presented.

The drinks reception (1900-1930) is open to anyone registered for the meeting without additional cost. If you would like to attend the dinner (1930) and have not yet registered for it, we have one or two spare spaces (£50) so please email Rhys Roberts [rcr20@cam.ac.uk (link sends e-mail)].

Corpus Christi College (http://www.corpus.cam.ac.uk (link is external)) is one of the oldest colleges (founded in 1352) in the University of Cambridge, situated in the heart of the City, providing a unique and historic setting for the joint meeting.

Accommodation is available near the college for those wishing to stay overnight.
Options include:
    Cambridge City Hotel http://www.cambridgecityhotel.co.uk/ (link is external)
    Double tree Hilton Cambridge <http://doubletree3.hilton.com/en/hotels/united-kingdom/doubletree-by-h%20ilton-hotel-cambridge-STNCBDI/index.html (link is external)>
    Speedy booker (College accommodation) <http://www.speedybooker.com/results.aspx?location=Cambridge&stay=true (link is external)&>

We look forward to welcoming you to Cambridge in the Spring!

Best wishes,
Rhys

--
Local organiser: Dr Rhys C Roberts FRCP PhD

Abstracts (can change before the event)

Title	Lead Author	Status
Can’t raise one eye brow- does it ring any Norwegian Bells?	Clare Galtrey	Finished Version	View
Capsaicin 8% patch treatment in small fibre neuropathy: from pain relief to disease modification	Praveen Anand	Finished Version	View
Audit of microneurography in diagnosis of small fibre neuropathy	Pietro Doneddu	Finished Version	View
The vital molecule	Barbara Wysota	Finished Version	View
‘Unblocking the Block’	Christina Englezou	Finished Version	View
Becoming an average CIDP patient	Eftimov	Finished Version	View
Cramp-fasciculation syndrome - an unexpected etiology	Nicolas Dubuisson	Finished Version	View
Trying to avoid cold whilst waiting for the next generation of analgesics	A Kelly	Finished Version	View
Human stem cell derived motor neurons to model multifocal motor neuropathy	Oliver Harschnitz	Finished Version	View

Programme

No Programme

Queen Square Annual Update in Neuromuscular Disorders

This course will be held from Wednesday 28th May to Friday 30th May in the Clinical Neuroscience Lecture Theatre, Lower ground, 33 Queen Square, London WC1N 3B

DETAILS/REGISTRATION

Brain Fellowships

Applications are invited for 1 year fellowships funded by the Guarantors of Brain. These fellowships provide bridging salary support to early career clinicians based in the UK prior to obtaining a research fellowship. Further details can be found HERE

Hereditary Neuropathy Serine Trial

The Hereditary Sensory Neuropathy Serine trial (SENSE trial) ClinicalTrials.gov Identifier: NCT06113055

The Hereditary Sensory Neuropathy Serine trial (SENSE trial) is open to recruitment. This is a randomised double-blind placebo-controlled trial of L-serine in Hereditary Sensory Neuropathy type 1 (HSN1) due to variants in SPTLC1/2 gene.

This is a single-centre study being conducted at the National Hospital for Neurology and Neurosurgery, London UK. The Chief Investigator for this trial is Professor Mary M Reilly. If you have any affected patients who you think may interested in taking part then please invite them to contact the trial team for further information.

Recruitment will close August 2024.

New NHSE commissioning policies for rituximab and IVIg

We are pleased to announce that, largely due to the efforts of our president Prof Lunn, rituximab is now approved for treatment of IgM paraproteinaemic demyelinating peripheral neuropathy (anti-MAG phenotype, with or without anti-MAG antibodies): 1910-rituximab-for-treatment-of-PDPN-policy-v2.pdf (england.nhs.uk). Whilst we have hitherto been able to treat some patients with rituximab by sending them to a haematologist, this was not possible if the bone marrow showed insufficient evidence of underlying lymphoplasmacytic lymphoma. These patients can now be treated, regardless of bone marrow result, either by you or by your friendly haematologist, under the new commissioning guidance.
Also thanks to Prof Lunn (alongside non-neurology colleagues), the updated IVIg commissioning policy is now available: Commissioning-Criteria-Policy-for-the-use-of-Ig-Version-Finala.pdf (mdsas.com). Newly commissioned diagnoses of relevance to peripheral nerve now include acute autoimmune autonomic ganglionopathy, and neuromyotonia.
Finally, with thanks largely to the efforts of Dr Rinaldi in Oxford, rituximab can now be used for the treatment of autoimmune nodopathies (with nodal/paranodal antibodies): NHS England » Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children.

More news »

Meetings

Queen Square Annual Update in Neuromuscular Disorders

Brain Fellowships

Hereditary Neuropathy Serine Trial

New NHSE commissioning policies for rituximab and IVIg